Loading
Every dated change on the records linked to Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Hydroxyurea (superior to etoposide in the randomised GFM trial); ruxolitinib in trials for symptomatic proliferative disease.
GFM randomised trial (Wattel et al., Blood).